Main Article Content
Clinical pharmacology, Aggrenox®, Dipyridamole, acetylsalicylic acid, acute renal failure
Aggrenox® is used in the secondary prevention of stroke. Acute renal failure, potentially associated with Aggrenox®, has been observed in several patients.
The objective of this study was to determine if Aggrenox® was associated with acute renal failure and to determine whether it was acetylsalicylic acid, dipyridamole or the combination that led to decline in renal function.
A case series of three patients suffering severe nausea, vomiting, diarrhea, renal dysfunction and clinical decline during Aggrenox® therapy was examined. Serum creatinine and Blood Urea Nitrogen (BUN) were measured to evaluate renal function.
Analysis of this patient group revealed that Patient 1 experienced nausea, emesis, anorexia, diarrhea and significant clinical decline during treatment with Aggrenox®. Patients 2 and 3 also presented with complaints of nausea and emesis. Lab measurements along with clinical symptoms indicated that all three patients experienced acute renal failure, having increases in serum creatinine of 186%, 144% and 249%, respectively. Symptoms and lab work returned to baseline following discontinuation of Aggrenox®.
It is biologically plausible that Aggrenox® may contribute to renal dysfunction in patients under certain pathophysiological circumstances.
2. Matura LA, Mengo PF. Guidelines for Diagnosis and Management of Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction. The Internet Journal of Advanced Nursing Practice. 2003;6.
3. Lopez Farre, AJ. Mechanism of action of acetylsalicylic acid (ASA). Available at: http://www.viva.vita.bayerhealthcare.com/index. php?id=36&tx_ttnews%5Btt_news%5D=10042&cHash=b1a67cfec2. [Accessed December 15, 2008].
4. American Society of Health-System Pharmacists. AHFS Drug Information. Bethesda, MD: American Society of Health- System Pharmacists, Inc., 2008.
5. Bendayan R. Interaction of dipyridamole, a nucleoside transport inhibitor, with the renal transport of organic cations by LLCPK1 cells. Can J Physiol Pharmacol. 1997;75:52-56. 6.
6. Sano N, Sato S, Hashimoto K. Differences among dipyridamole, carbochromen and lidoflazine in responses of the coronary and the renal arteries. Jpn J Pharmacol. 1972;22:857- 865.
7. Spielman WS, Arend LJ. Adenosine receptors and signaling in the kidney. Hypertens. 1991;17:117-130.
8. Hall JE, Granger JP. Adenosine alters glomerular filtration control by angiotensin II. Am J Physiol. 1986;250:F917-F923.
9. Spielman WS, Osswald H. Blockade of postocclusive renal vasoconstriction by an angiotensin II antagonists: evidence for an angiotensin-adenosine interaction. Am J Physiol. 1979;237:F463-F467.
10. Arend LJ, Thompson CI, Spielman WS. Dipyridamole decreases glomerular filtration in the sodium-depleted dog. Evidence for mediation by intrarenal adenosine. Circ Res. 1985;56:242-251.
11. Llach J, Gines P, Arroyo V, et al. Effect of dipyridamole on kidney function in cirrhosis. Hepatology. 1993;17:59-64.
12. Latham TB, Prato FS, Wisenberg G, Reese L. Effects of dipyridamole infusion on human renal function observed using technetium-99m-DTPA. J Nucl Med. 1992;33:355-358.
13. Katholi RE, Taylor GJ, McCann WP, et al. Nephrotoxicity from contrast media: attenuation with theophylline. Radiology. 1995;195:17-22.
14. Arend LJ, Bakris GL, Burnett JC, Jr., Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic response to contrast media. J Lab Clin Med. 1987;110:406-411.
15. Deray G, Martinez F, Cacoub P, Baumelou B, Baumelou A, Jacobs C. A role for adenosine calcium and ischemia in radiocontrast-induced intrarenal vasoconstriction. Am J Nephrol. 1990;10: 316-322.
16. Seideman P, Sollevi A, Fredholm BB. Additive renal effects of indomethacin and dipyridamole in man. Br J Clin Pharmacol. 1987;23:323-330.
17. Al Hwiesh A. Aggrenox-associated acute interstitial nephritis. Saudi J Kidney Dis Transpl. 2006;17:50-53.
18. Shaver MJ, Shah SV. Nephrology: Acute Renal Failure. In: Federman DD, Nabel EG, eds. ACP Medicine. New York, NY: BC Decker Inc., 2009.
19. Feinfeld DA, Anthony VL. Renal Principles. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS, eds. Goldfrank's Toxicologic Emergencies. New York, NY: The McGraw-Hill Companies, Inc., 2006: 427-441.
20. Amend WJC, Vincenti FG. Oliguria: Acute Renal Failure. In: Tanagho EA, McAninch JW, eds. Smith's General Urology. New York, NY: Lange Medical Books/McGraw-Hill, Medical Publishing Division, 2008: 531-534.
21. Singri N, Ahya SN, Levin ML. Acute renal failure. J Am Med Assoc. 2003;289:747-751.
22. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care. 2004;8:R204-R212.
23. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417-430.
24. Kumar S, Stein JH. Acute Renal Failure. In: Stein JH, ed. Internal Medicine. Mosby, Inc., 1998: 768-775.
25. Ross JE. Diseases of the Kidney. In: Taylor RB, ed. Family Medicine: Principles and Practice. New York, NY: Springer-Verlag New York, Inc., 2003: 833-840.
26. Tello R, Hartnell GG, Hill T, Volpe J, Finn JP, Cohen M. MR perfusion imaging of the kidney pre- and post-dipyridamole stress. J Magn Reson Imaging. 1996;6:460-464.
27. Redlak M, Szczepanska-Konkel M, Stepinski J, Angielski S. Effects of dipyridamole and furosemide on renal function during adenine dinucleotide infusion in rats. Acta Physiol Pol. 1986;37:1-7.